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Gitte J Almind1*, Jakob Ek2, Thomas Rosenberg3, Hans Eiberg4, Michael Larsen3,5, LuCamp LuCamp6,
Karen Brøndum-Nielsen1,4 and Karen Grønskov1,4Abstract
Background: Investigation of the OPA1 mutation spectrum in autosomal dominant optic atrophy (ADOA) in
Denmark.
Methods: Index patients from 93 unrelated ADOA families were assessed for a common Danish founder mutation
(c.2826_2836delinsGGATGCTCCA) inOPA1. If negative, direct DNA sequencing of the coding sequence and multiplex
ligation-dependent probe amplification (MLPA) were performed. Results from MLPA analysis have been previously
reported. Haplotype analysis was carried out analysing single nucleotide polymorphisms (SNP). Retrospective clinical
data were retrieved from medical files.
Results: Probably causative mutations were identified in 84 out of 93 families (90%) including 15 novel mutations.
Three mutations c.983A >G, c.2708_2711delTTAG and c.2826_2836delinsGGATGCTCCA, were responsible for ADOA
in10, 11 and 28 families, respectively, corresponding to 11%, 12% and 30%. A common haplotype in nine of ten
c.983A >G families suggests that they descend from a single founder. The c.2708_2711delTTAG mutation was
present on at least two haplotypes and has been repeatedly reported in various ethnic groups,thus represents a
mutational hotspot. Clinical examinations of index patients with the two latter mutations demonstrated large
inter- and intra-familial variations apparently.
Conclusions: Genetic testing for OPA1mutations assist in the diagnosis. We have identified mutations in OPA1 in
90% of families including 15 novel mutations. Both DNA sequencing and MLPA analysis are necessary to achieve a
high detection rate. More than half of the affected families in Denmark are represented by three common
mutations, at least two of which are due to a founder effect, which may account for the high prevalence of ADOA
in Denmark.
Keywords: OPA1, Optic atrophy, Optic atrophies, Hereditary, Autosomal dominant, ADOA, Genetics, Optic
neuropathies, Optic nerve, Genotype, PhenotypeBackground
Autosomal dominant optic atrophy (ADOA) is charac-
terized by bilateral visual loss, preferential temporal disk
pallor, dyschromatopsia, relative or absolute centrocoe-
calscotoma, and subnormal thickness of the retinal gan-
glion cell and nerve-fiber layers. The disease has
incomplete penetrance and variable expressivity, ranging* Correspondence: gij@kennedy.dk
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reproduction in any medium, provided the orfrom subclinical visual dysfunction to legal blindness.
The highly variable phenotype, both within and between
families, suggests that modifier genes and/or environ-
mental factors influence the expression of the disease.
The prevalence of 1:12,000 in Denmark is remarkably
high compared to 1:35,000 in other populations. [1,2]
Monosymptomatic optic atrophy shows genetic hetero-
geneity with at least eight loci; OPA1 (OMIM 605290) is
the major ADOA gene. OPA2 (OMIM 311050) has been
mapped to Xp11.4-p11.21, mutations in the OPA3 gene
(OMIM 606580) have been reported in ADOALtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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OPA4 (OMIM 605293) has been mapped to chromo-
some 18q12.2-q12.3, OPA5 (OMIM 610708) to chromo-
some 22q12.1-q13.1 and OPA6 (OMIM 258500) to
chromosome 8q. OPA7 (OMIM 612989) is caused by
mutations in TMEM126A (OMIM 612988). [4] Recently
the OPA8 locus has been mapped to chromosome
16q21-q22 [5].
OPA1is located on chromosome 3q28-q29, [6,7] and
more than 200 unique pathogenic mutations associated
with Kjer-type optic atrophy (OMIM 165500) have been
identified (http://lbbma.univ-angers.fr/eOPA1). [8] Muta-
tion detection rates of OPA1 in ADOA patients rangefrom
32% to 89%. [9-11] Aninsertion and deletion mutation in
exon 28 (c.2826_2836delinsGGATGCTCCA) causing a
frameshift has previously been shown to be common in
Denmark due to a founder effect [12].
OPA1 spans approximately 100 kb and is composed of
30 coding exons. Alternative splicing generates several
isoforms. The main isoform is 960 amino acids long,
encoded by 28 exons. The OPA1 protein is a ubiqui-
tously expressed mitochondrial protein with similarity to
dynamin-related GTPases.
Here we report the results of molecular genetic ana-
lyses of ADOApatients from Denmark. We identified
two frequent mutations, besides the already known fre-
quent founder mutation, and provide evidence for a
founder effect in one and a probable mutational hotspot
in the other. We report clinical data from families with
the two new frequent mutations.Methods
Patients
The cohort consisted of unrelated index patients from
93 families of Danish origin, clinically diagnosed with
ADOA. In total 266 family members, 210 affected and
56 unaffected individuals were studied. Only cases from
families with at least two affected members and a pat-
tern compatible with autosomal dominant inheritance
were included.
The diagnosis was based on routine clinical proce-
dures, including refraction and determination of best-
corrected visual acuity, color vision testing (various
combinations of Farnsworth 100, Farnsworth-Roth 28,
Americal Optical Hand-Hardy-Rittler, Farnsworth 15
Standard, Farnsworth 15 unsaturated, Lantony’sTritan
album, and Nagel’s anomaloscope), direct ophthalmos-
copy, slitlampbiomicroscopy of the anterior segment, vit-
reous, and posterior pole, fundus photography, Goldmann
manual kinetic perimetry, and visual evoked potential
recording. Clinical data from 19 families with one of two
frequent mutations were retrospectively retrieved from a
period of several decades.The study followed the tenets of the Declaration of
Helsinki and was approved by the local medical ethics
committee (The Ethical Committee of Central Region
(De VidenskabsetiskeKomiteer for Region Hovedstaden)
H-B-2007-110). Patients and healthy relatives were
informed of the nature of the study and written
informed consent was obtained.
Molecular genetic studies
Genomic DNA was extracted from leucocytes using
Chemagic Magnetic Separation Module I (Chemagen,
Baesweiler, Germany).
Analysis for c.2826_2836delinsGGATGCTCCA was per-
formed by two separate PCR reactions using one common
primer (OPA1R: TTG ATA GAC TAT AGG CAA GAA
GAA) together with either a primer specific for the
mutated allele (OPA1mutF: ACA GAG AAA GTG GAT
GCT CC) or a primer specific for the wild type allele
(OPA1wtF: CCA CAG AGA AAG TTA GAG AAA TTC).
Fiftynanogram of genomic DNA was amplified in 30 μl vol-
ume using 10 pmol of each primer and AmpliTaq-Gold
polymerase (Applied Biosystems, Foster City, CA, USA),
with initial denaturation for 5 minutes at 95°C followed by
40 cycles of 95°C for 30 seconds, 56°C for 45 seconds and
72°C for 60 seconds, and a final extension at 72°C for 10
minutes. PCR products were analysed on agarose gel and
ethidium bromide staining using standard methods.
DNA sequencing was performed of all 30 coding regions
plus 20 bp of flanking sequences by PCR amplification
using 50 ng of genomic DNA in a 50 μl volume using
AmpliTaq Gold polymerase and 15 pmol each primer (see
Additional file 1 for primer sequences). After initial de-
naturation at 95°C for 10 minutes, the samples were amp-
lified for 35 cycles at 95°C for 30 seconds, 60°C for 30
seconds and 72°C for 30 seconds; final extension for 9
minutes at 72°C. Bidirectional sequencing was performed
using BigDye v3.1 chemistry and ABI3130 (AppliedBiosys-
tems). SeqScape software (version 2.5; Applied Biosys-
tems) was used for analysis using reference sequence
GenBank accession number NG_011605.1. GenBank tran-
script NM_015560 was used for numbering the variants
with A in ATG as number 1.
Haplotype analysis was performed analysing 14 SNP’s
surrounding the OPA1 gene (position chr3:188,391,767–
196,005,479, human genome version hg19/GRCh37)
(Table 1). The analysis was performed by KBiosciences
(Hoddesdon, Herts, United Kingdom). SNPs with minor
allele frequency >25% in European descendents were
selected for the study.
Investigation of c.1313A>C, c.1376 G>A and
c.2496 G>C in a control group, was performed by search-
ing the gene database generated by LuCamp (www.lucamp.
org) by whole exome sequencing (average coverage of X 8)
[13] of 1000 healthy Danish controls and 1000 Danish
Table 1 Haplotype analysis
A
Family DOA 139 141 142 143 144 145 146 147 148 140
Affected 1 7 3 2 6 6 11 2 3 3
Unaffected 1 2
SNP Position
rs6796000 188,391,767 T T T T T T T T T T
rs4677728 191,093,560 A A A G A A A A A T
rs4453795 192,094,225 A A A A A A A G A T
rs3905277 192,983,948 A A A A A A A A A T
rs6788448 193,209,428 C C C C C C C C C TC
rs11922359 193,290,262 A A A A A A A A A A
rs9868128 193,299,458 A A A A A A A A A TA
OPA1 193,310,933-193,415,599
rs1007408 193,475,519 C C C C C C C C C G
rs11915891 193,488,257 C C C C C C C C C T
rs6770515 193,490,499 A A A A A A A A A A
rs9854346 193,492,100 A A A A A A A A A A
rs9866505 193,676,362 C C C C C C C C C T
rs4677655 194,826,387 T T T C T T T T T T
rs3772109 196,005,479 T T T C C T T T T T
B
Family DOA Position 149 150 151 152 153 154 155 156 157 158
Affected 5 2 3 6 2 1 5 3 1 1
Unaffected 2 1 1 3 2
SNP Position
rs6796000 188,391,767 T T T T T T:T T T T:T T:T
rs4677728 191,093,560 A A A A A G:A G G A:A G:A
rs4453795 192,094,225 G GA A A A A:A G G G:A A:A
rs3905277 192,983,948 A G G G G G:G G A G:A A:A
rs6788448 193,209,428 T TC TC C C C:C T T T:C T:C
rs11922359 193,290,262 A A A A A A:A T T A:A A:A
rs9868128 193,299,458 A A A A A A:A T T A:A A:A
OPA1 193,310,933-193,415,599
rs1007408 193,475,519 C GC GC GC G G:C GC C G:G G:C
rs11915891 193,488,257 C TC T T TC T:C C C T:T T:C
rs6770515 193,490,499 G G GC G GA G:G G G G:G G:G
rs9854346 193,492,100 T T T T TA T:T T T T:T T:T
rs9866505 193,676,362 C TC T T TC T:C C C T:T T:C
rs4677655 194,826,387 TC TC TC C T T:C TC T T:T T:C
rs3772109 196,005,479 T TC T T T T:T T T T:T T:T
Position numbers according to hg19.
A) Analysis of 10 families with c.983A >G mutation in exon 9.
B) Analysis of 10 families with c.2708_2711delTTAG mutation in exon 27.
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betes, obesity and hypertension (Additional file 2).
Results
Results from mutational analysis are shown in Table 2.
The c.2826_2836delinsGGATGCTCCA mutation wasfound in 28 index patients. This mutation causes a
frameshift and extension of the protein beyond the nor-
mal stopcodon (p. Arg943Aspfs*25). Sixty-five patients
were left for further investigation. MLPA analysis
showed deletions in 10 index patients, as previously
reported. [14] In the remaining 55 index patients, DNA





Type Exon/Intron Domain No of families
(affected/unaffected)
c.113_130del18 [15] p. Arg38_Ser43del Deletion
(in-frame deletion)
Exon 2 Basic Domain 1 (2+/1-)
c.356_357delTT Novel p. Phe119X* Deletion (nonsense) Exon 3 Basic Domain 1 (2+/2-)
c.815 T > C [16] p. Leu272Pro Substitution (missense) Exon 8 GTPase Domain 1 (1+)
c.983A>G [16] p. Val291_Lys328del Substitution (splice,
deletion in-frame)
Exon 9 GTPase Domain 10 (43+/5-)
c.984 G>A [11,16] p. Lys328Lys Substitution (splice) Exon 9 GTPase Domain 1 (1+)
c.984 + 1 G> T Novel Unknown Substitution (splice) Intron 9 GTPase Domain 1 (1+)
c.1140 + 1 G> T Novel Unknown Substitution (splice) Intron 11 GTPase Domain 1 (1+)
c.1304_1305delGT [15] p. Cys435Tyrfs*9 Deletion (frameshift with
premature stop)
Exon 13 GTPaseDomain 1 (4+)
c.1313A>C Novel p. Asp438Asp Substitution (missense*) Exon 14 GTPase Domain 1 (1+)
c.1376 G>A Novel p. Gly459Glu Substitution (missense) Exon 14 GTPase Domain 1 (1+/2-)









































c.2613 + 1 G>C Novel Unknown Substitution (splice) Intron 25 1 (2+/2-)
c.2614-9A>G [18] Unknown Substitution (splice) Intron 25 1 (7+)
c.2707 + 1 G>C Novel Unknown Substitution (splice) Intron26 4 (5+/1-)
c.2708_2711delTTAG [2,9-11,15,
16,19-21]
p. Val903Glyfs*3 Deletion (frameshift
with premature stop*)
Exon 27 11 (29+/14-)
c.2713 C> T [10] p. Arg905X* Substitution (nonsense) Exon 27 1 (2+)
c.2728_2730 delGTT Novel p. Val910del Deletion
(in-frame deletion)
Exon 27 1 (8+/1-)
c.2826_2836delins
GGATGCTCCA
[15,19] p. Arg943Aspfs*25 Deletion/insertion
(frameshift
with extension)
Exon 28 28 (58+/18-)
*Based on silico analysis pathogenic. Chromatographs for novel mutations are shown in Additional file 4.
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Figure 1 Visual acuity converted from Snellen acuities into Log
Mar. Figure A includes 35 patients with c.983A>G mutation and
figure B includes 21 patients with c.2708_2711delTTAG mutation.
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46 families including 15 novel mutations. The sequence
variations were consisting of 16 nucleotide substitutions,
six deletions, one insertion andtwo indels. On the pro-
tein level the sequence variations were predicted to
cause three in-frame deletions, four nonsense mutations,
fourmissense mutations, nine splice mutations and five
frameshifts causing premature translation stop.
Fifteensequence variations were novel; of these, eleven
introduced a premature stopcodon, caused deletion of
an amino acid or were located in consensus splice sites.
Threewere nucleotide substitutions, c.1313A>C,
c.1376 G>A and c.2496 G>C. The c.1313A>C muta-
tion is located as the first basepair in exon 14. In silico
analysis using the splice site prediction of Berkeley Dros-
ophila Genome Project (http://www.fruitfly.org/seq_-
tools/splice.html) predicts that c.1313A>C does not
affect the splice site. Thus, this sequence variation prob-
ably causes a missense mutation p. Asp438Ala, predicted
by SIFT (http://sift.jcvi.org/) to be damaging (SIFT score
0.01) and by Polyphen2 (http://genetics.bwh.harvard.
edu/pph2/) to be probably damaging (Polyphen2 score
1.0). The c.1376 G>A variation is predicted to cause an
aminoacid substitution, p. Gly459Glu, which is predictedto be pathogenic with SIFT score 0 and Polyphen2 score
1.0 and is probably a pathogenic missense mutation.
Two unaffected family members did not have the vari-
ation.C.2496 G>C is the last basepair in exon 24 and is
predicted by in silico analysis to destroy the donor splice
site. Three unaffected family members did not have the
variation. These three nucleotide substitutions no family
members were available for segregation, however none
were present in 1070 healthy Danish controls and 1000
Danish individuals with metabolic phenotypes (described
under Materials and Methods section Molecular Genetic
Studies). The indel c.2496 + 4_2496 + 5delinsGTAAC is
located in intron 24. In silico analysis predicts that it
destroys the splice site. The mutation segregated with the
disease in this family (five affected and one unaffected).
Two sequence variations, c.983A>G and c.2708_
2711delTTAG were present in 10 and 11 families, respect-
ively. The c.983A>G mutation is reported to cause skip-
ping of exon 9, resulting in an in-frame deletion of 38
amino acids. [16] The c.2708_2711delTTAG mutation is
located as the first four nucleotides in exon 27. [2,9-
11,15,16,19-21] Insilico analysis of the splice site predicts
normal splicing; thus the sequence variation is predicted
to cause a frameshift with incorporation of two amino-
acids followed by a premature stop codon (p. Val903-
Glyfs*3). Haplotype analysis was performed using both
affected and unaffected individuals from 10 families
with c.983A >G and 10 families with c.2708_2711delT-
TAG (Table 1). Nine out of 10 families with c.983A>G
shared the same haplotype of size 1,8 Mb while one family
had a different haplotype distal to OPA1. At least two hap-
lotypes were present for c.2708_2711delTTAG.
Analysis of the clinical characteristicsof affected indivi-
duals with c.983A>G or c.2708_2711delTTAG revealed a
broad spectrum of phenotype variation in both groups
(Figure 1 and Additional file 3). For c.983A>G the age at
clinical onset varied from 3 to 62 years of age (mean 13.8,
median 7 years) while visual acuity ranged from 6/6 to 2/
60. For c.2708_2711delTTAG the age at clinical onset var-
ied from 3 to 48 years of age (mean 13.3, median 8 years)
and visual acuity also ranged from 6/6 to 2/60. Figure 1
shows the visual acuities converted from Snellen acuities
into Log Mar. A very large intrafamilial variation is evident
and there is no obvious difference between the two groups
of patients. The distribution seems to be dichotomous,
one clusterhaving visual acuities 6/18 (Log Mar 0.5) or
above, the other cluster with visual acuities 6/24 (Log Mar
0.6) or below. Among the two mutation groups 57% and
54% was in the best visual acuitycluster. There was no
clear effect of age and in broad terms the full spectrum of
variation in visual acuity was present throughout the age
range that was surveyed. Patients for whom data from
more than one examination was available (Figure 1)
showed considerable variations in the rate of acuity loss.
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defects being common and with no correlation to visual
acuity. Additionally, some patients had red-green defects
of different magnitudes, whileothers had no detectable
color vision defect. Full-field visual evoked potentials
(ffVEP) were ofreduced amplitudes and somewhat prolon-
gedlatencies with occasionalabnormal configurations,
including “spike-trains”. Pattern VEP (pVEP) regularlypre-
sented reduced or nearly undetectable amplitudes,
but some patients had both normal ffVEP and pVEP
even despite having moderately reducedvisual acuity. The
most frequent clinical sign was temporal pallor of the
optic discs.
Discussion
In 84 of the 93 index patients (90%) we found sequence
variations that were either obviously pathogenic or pre-
dicted to be pathogenic by in silico analysis. 53% were
attributableto one of only threesequence variations
(c.983A>G, c.2708_2711delTTAG, or c.2826_2836delinsG-
GATGCTCCA). This might explain the high prevalence
1:12,000 of Kjer-type optic atrophy in Denmark. The high
mutation detection rate may reflect the clinical selection of
the cohort from families with affected individuals in at least
two generations and compatibility with autosomal domin-
ant inheritance.
On the basis of the present study and the previously
published MLPA study have lead us to perform muta-
tional analysis in the most cost-effective manner: initially
targeted analysis for c.2826_2836delinsGGATGCTCCA
followed by MLPA analysis for deletions and duplica-
tions are performed. If these are negative, exon 9 and
exon 27 are sequenced. In Danish patients this proced-
ure can be expected to detect causative mutations in
more than 60% of cases. Obviously, this strategy only ap-
plies to Danish ADOA patients, however, it must be
emphasized that for other populations the fraction of
deletions detectable by MLPA analysis and mutations
detectable by DNA sequence analysis must be deter-
mined and probably both kinds of analyses must be per-
formed to achieve a high detection rate.
In nine patients we did not detect pathogenic muta-
tions. This might be due to mutations in regions not
investigated (deep intronic mutations or mutations in
regulatory regions) or mutations in other genes.
The two frequent mutations, c.983A>G and
c.2708_2711delTTAG, have been reported previously in
other ethnic groups. [2,9-11,15,16,19-21] Wefound evi-
dence for a founder effect of c.983A >G while
c.2708_2711delTTAG seems to be a mutational hotspot.
Clinical details of patients with c.983A >G mutation
versus patients with c. 2708_2711delTTAG mutation
revealed no obvious differences with respect to age at
onset, visual acuity, refractive values, progression rate,color vision or VEP. In our study temporal pallor of the
optical disc was the most constant clinical finding. This
observation is in disagreement with the observations of
Votruba et al. [22], who found a significant fraction of
patients with a diffuse disc atrophy. The studydemon-
strates no correlation between the included clinical para-
meters. The clinical data analysis is retrospective,
however, and based on records collected over a long
period where diagnostic practices may have varied.
Nevertheless, thephenotype variation is conspicuous,
even among patients with one and the same mutation.
This allows for considerable optimism concerning the
search for genes and environmental factors that modify
the impact of OPA1 mutations on the mitochondrial ma-
chinery and the associated phenotypes.
Conclusions
Based on mutational analysis of Danish patients with
ADOA we conclude that genetic testing for OPA1muta-
tions assist in the diagnosis. Using a strategy based on
MLPA analysis and DNA sequencing we have identified
mutations in OPA1 in 90% of families including 15 novel
mutations. More than half of the affected families in Den-
mark are represented by three common mutations.
Additional files
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Additional file 2: LuCamp partner list.
Additional file 3: Clinical findings from families with c.983A>G and
c.2708_2711delTTAG mutations.
Additional file 4: Chromatographs for novel mutations.
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